Table 3.
Substance use and treatment characteristics of study sample (N = 46)
| Characteristic | % (n) |
|---|---|
| Severity of substance use at admissionb | |
| Moderate/Severed | 84% (36 of 43) |
| History of polysubstance useb | 57% (26) |
| History of injection drug use | 50% (23) |
| Lifetimeb | 50% (23) |
| 30 days prior to incarceration | 37% (17) |
| Non-OAT substance use services used (30 days prior to incarceration)a | |
| Harm reduction services | 46% (21) |
| Outpatient treatment | 17% (8) |
| Support groups | 15% (7) |
| Inpatient treatment | 9% (4) |
| Engagement in OAT (30 days prior to incarceration) | 44% (20) |
| Type(s) of OAT (30 days prior to incarceration)ac | |
| Methadone | 95% (19 of 20) |
| Buprenorphine-naloxone | 5% (1 of 20) |
| Both Methadone and buprenorphine-naloxone | 10% (2 of 20) |
| Hydromorphone | 5% (1 of 20) |
| Entered CSC on OAT | 39% (18) |
| Type(s) of OAT during CSC incarcerationb | |
| Methadone | 67% (31) |
| Buprenorphine-naloxone | 33% (15) |
aResponses not mutually exclusive
bData acquired from CSC
cResponses out of n = 20 participants who indicated they had been engaged in OAT 30 days prior
dResponses out of n = 43 participants who had this data; Severity of substance use is determined using CASA. Harm reduction category includes use of either needle exchange, safer use kits, naloxone kits, etc.; Outpatient treatment category includes either group therapy, one-on-one therapy/counseling, relapse prevention; Inpatient treatment category includes residential treatment, rehabilitation, detoxification/withdrawal management; Support groups include self-help or mutual aid groups such as alcoholics anonymous, narcotics anonymous, etc.